It is imperative that Clinical Utility Indices (CUIs) be developed that can rapidly convey composite information encompassing druggability/likelihood of clinical benefit that is context dependent (e.g. disparity of connotations of BRAF mutations in melanoma versus colorectal cancer) and associated level of evidence ranging from pre-clinical only to definitive clinical studies. This evidence concerns the gene BRAF and melanoma.